Cancer Biomark. 2019;25(3):243-250. doi: 10.3233/CBM-190058.
The aim of this study was to evaluate the prognostic value of a novel tumor marker index (TMI) based on preoperative serum levels of squamous cell carcinoma antigen (SCC) and cytokeratin 19 fragment (CYFRA 21-1) for patients with resectable esophageal squamous cell carcinoma (ESCC).
A total of 315 ESCC patients who had underwent curative surgery between 2008 and 2012 were retrospectively included in this study. The TMI was defined as the geometric mean of normalized SCC and CYFRA21-1 levels. Univariate and multivariate survival analyses were performed to confirm the clinical and prognostic significance of preoperative SCC and CYFRA 21-1 levels and TMI.
Elevated preoperative SCC was associated with histological grade, pT status, lymph node status and TNM stage. Elevated preoperative CYFRA 21-1 was correlated with tumor size, lymph node status and TNM stage. The overall survival of patients with elevated SCC and CYFRA 21-1 levels was significantly poorer than that of patients with normal levels. Multivariate survival analysis identified that preoperative SCC (P= 0.353) and CYFRA 21-1 (P= 0.139) were not independent prognostic factors. The cut-off value of TMI based on SCC and CYFRA 21-1 was 0.531, and the patients were subdivided into high and low TMI groups. The 5-year survival rate of patients with high TMI was 30.9%, which was significantly lower than that of patients with low TMI (50.4%, P< 0.05). Multivariate analysis identified the TMI (HR 1.371; 95% CI 1.024-1.836; P= 0.034) as an independent prognostic factor.
Elevated preoperative SCC and CYFRA 21-1 levels were associated with aggressive cancer behavior in ESCC. The TMI based on preoperative SCC and CYFRA 21-1 might serve as a novel marker that can be used to predict the prognosis of ESCC patients.
本研究旨在评估基于术前血清鳞状细胞癌抗原(SCC)和细胞角蛋白 19 片段(CYFRA 21-1)水平的新型肿瘤标志物指数(TMI)对可切除食管鳞状细胞癌(ESCC)患者的预后价值。
回顾性纳入 2008 年至 2012 年间接受根治性手术的 315 例 ESCC 患者。TMI 定义为标准化 SCC 和 CYFRA21-1 水平的几何平均值。进行单因素和多因素生存分析以确认术前 SCC 和 CYFRA 21-1 水平和 TMI 的临床和预后意义。
术前 SCC 升高与组织学分级、pT 分期、淋巴结状态和 TNM 分期有关。术前 CYFRA 21-1 升高与肿瘤大小、淋巴结状态和 TNM 分期有关。SCC 和 CYFRA 21-1 水平升高患者的总生存率明显低于正常水平患者。多因素生存分析表明,术前 SCC(P=0.353)和 CYFRA 21-1(P=0.139)不是独立的预后因素。基于 SCC 和 CYFRA 21-1 的 TMI 截断值为 0.531,将患者分为高和低 TMI 组。高 TMI 组患者的 5 年生存率为 30.9%,明显低于低 TMI 组(50.4%,P<0.05)。多因素分析表明 TMI(HR 1.371;95%CI 1.024-1.836;P=0.034)是独立的预后因素。
术前 SCC 和 CYFRA 21-1 水平升高与 ESCC 侵袭性癌症行为有关。基于术前 SCC 和 CYFRA 21-1 的 TMI 可能是一种新的标志物,可用于预测 ESCC 患者的预后。